<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25152759</article-id><article-id pub-id-type="pmc">4131450</article-id><article-id pub-id-type="doi">10.1155/2014/217397</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of Acupuncture on Leucopenia, Neutropenia, NK, and B Cells in Cancer Patients: A Randomized Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pais</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Correia</surname><given-names>Nuno</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pimentel</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Teles</surname><given-names>Maria Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Neves</surname><given-names>Esmeralda</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vasconcelos</surname><given-names>J&#x000fa;lia</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>Judite</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Azevedo</surname><given-names>Nancy</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moreira Pinto</surname><given-names>Ant&#x000f3;nio</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Machado</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Efferth</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I9">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Greten</surname><given-names>Henry J.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I10">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Instituto Ci&#x000ea;ncias Biom&#x000e9;dicas Abel Salazar, Universidade do Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal</aff><aff id="I2"><sup>2</sup>Service of Emergency, Internal Medicine, Hospital Center of S. Jo&#x000e3;o, Oporto, Portugal</aff><aff id="I3"><sup>3</sup>Service of Oncology, Hospital Center of S. Jo&#x000e3;o, Oporto, Portugal</aff><aff id="I4"><sup>4</sup>Service of Clinical Pathology, Hospital Center of S. Jo&#x000e3;o, Oporto, Portugal</aff><aff id="I5"><sup>5</sup>ISPUP-EPI Unit, Institute of Public Health, University of Oporto, Portugal</aff><aff id="I6"><sup>6</sup>Service of Clinical Pathology, Porto Hospital Center, Oporto, Portugal</aff><aff id="I7"><sup>7</sup>Department of Oncology, Hospital Center of Vila Nova de Gaia/Espinho, Portugal</aff><aff id="I8"><sup>8</sup>Oporto Biomechanics Laboratory, Portugal</aff><aff id="I9"><sup>9</sup>Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Germany</aff><aff id="I10"><sup>10</sup>Heidelberg School of Chinese Medicine, Germany</aff><author-notes><corresp id="cor1">*Irene Pais: <email>irene.mtc@gmail.com</email></corresp><fn fn-type="other"><p>Academic Editor: Nobuo Yamaguchi</p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>217397</elocation-id><history><date date-type="received"><day>3</day><month>3</month><year>2014</year></date><date date-type="rev-recd"><day>1</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>3</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Irene Pais et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Chemotherapy is one of most significant therapeutic approaches to cancer. Immune system functional state is considered a major prognostic and predictive impact on the success of chemotherapy and it has an important role on patients' psychoemotional state and quality of life. In Chinese medicine, chemotherapy is understood as &#x0201c;toxic cold&#x0201d; that may induce a progressive hypofunctional state of immune system, thus compromising the fast recovery of immunity during chemotherapy. In this study, we performed a standardized acupuncture and moxibustion protocol to enhance immunity in cancer patients undergoing chemotherapy and to assess if the improvement of immunity status correlates with a better psychoemotional state and quality of life.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Colorectal cancer (CRC) is one of the most common cancers and a major cause of death due to cancer worldwide. The functional state of the host immune system has a major prognostic and predictive impact on the fate of cancer patients treated with conventional or targeted chemotherapies [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>According to the immunoediting theory [<xref rid="B2" ref-type="bibr">2</xref>], cancer cells and immune cells reciprocally modulate each other and the two possible outcomes are either the elimination or escape of tumour cells. NK cells are considered to represent a<italic> first line of defence against the metastatic spread of tumour cells</italic>. This idea is supported by the report of an association between the decreased activity or low numbers of circulating NK cells with progression of cancers and correlation between an absolute decrease in the activity of the NK cells and an absolute decrease in the lytic potential of these cells [<xref rid="B3" ref-type="bibr">3</xref>]. As effector members of the innate immunity, NK cells play a major role in anti-infection activity and tumour surveillance. NK cells can directly kill target cells to which they are capable of adhering within 1 to 4 hours without prior activation, priming or assistance by cytokines. NK cells have been recognized as major producers of cytokines in many physiological and pathological conditions, such as interferon <italic>&#x003b3;</italic> (IFN<italic>&#x003b3;</italic>), tumour necrosis factor (TNF<italic>&#x003b1;</italic>), and interleukin-10 (IL-10), as well as growth factors such as granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and IL-3. NK cells also secrete several chemokines, which are vital for their colocalization with other hematopoietic cells such as dendritic cells (DC) in areas of inflammation.</p><p>Recent studies [<xref rid="B4" ref-type="bibr">4</xref>] provide the notion that tumour-induced alterations of activating NK cell receptor expression may hamper immune surveillance and promote tumour progression and reveal that NK cell activity is reduced in patients with metastatic CRC, pointing out to NK cells as a first line of defence against metastasis.</p><p>According to psychoneuroimmunology theory, psychological and emotional stress induces several alterations in diverse biological responses. The activation of the<italic> hypothalamic-pituitary-adrenal axis</italic> (HPA) and the<italic> sympathetic nervous system </italic>(SNS) may generate a change in the immune cell traffics and promotes inflammation via multiple neuroendocrine and immune pathways. Higher stress levels were associated with poorer immune responses (low NK cell activity) and the stress reduction with improvement of immune responses, in women with breast cancer [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>Humoral and, especially, cellular immune functions have been reported as being boosted by acupuncture and moxibustion in cancer patients with significant increases in several T lymphocyte subsets. Immune system modulation has been noted also for various other conditions, such as asthma and autoimmune and inflammatory diseases [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>].</p><p>A review on the ascribed immunomodulation of acupuncture concludes that acupuncture treatment appears to be able to modulate immunosuppressed or immunoactivated conditions through different mechanisms, including macrophages, neutrophils, NK cells and lymphocytes stimulation, immunoglobulin production, and complement system activation [<xref rid="B8" ref-type="bibr">8</xref>]. In fact, two possible implicated mechanisms were previously reported: NK-related gene expression in the spleen [<xref rid="B9" ref-type="bibr">9</xref>] and the sympathetic nervous system [<xref rid="B10" ref-type="bibr">10</xref>]. Another study revealed that acupuncture enhances the NK cells activity and modulates the balance between Th1 and Th2 [<xref rid="B11" ref-type="bibr">11</xref>].</p><p>We aimed to evaluate the effect of acupuncture on the immune system (namely, on WBC, ANC, lymphocytes, and NK cells activity) on CRC patients and assess if the ascribed immunomodulatory effects of acupuncture have implications on patients' psychoemotional state and quality of life.</p></sec><sec id="sec2"><title>2. Patients and Methods</title><sec id="sec2.1"><title>2.1. Selection of Patients</title><p>This study was approved by the Ethics Committee of S. Jo&#x000e3;o and Vila Nova de Gaia/Espinho Hospital Centers, Oporto, Portugal. Written informed consent was obtained from all patients before study enrollment. Patients were eligible for inclusion as follows: recently diagnosed or recurrent colorectal cancer, regardless of stage, receiving chemotherapy, no regular use of acupuncture within 120 days prior to enrollment, ability to give informed consent, and &#x0003e;18 years of age. Exclusion criteria were the following: (a) absolute neutrophil count (ANC) less than 500/<italic>&#x003bc;</italic>L, (b) platelet count less than 25,000/<italic>&#x003bc;</italic>L, (c) altered mental state, (d) clinically significant cardiac arrhythmias, and (e) other unstable medical conditions.</p></sec><sec id="sec2.2"><title>2.2. Study Design</title><p>All patients enrolled were evaluated at baseline. Patients were randomized into one of two groups: active acupuncture (AcuMoxa) or nonacupuncture (control group). All of the study patients were blinded to randomization assignments (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Patients in the experimental group received 6 sessions of acupuncture, twice a week, beginning one week prior to cycle of chemotherapy and ending at the beginning of the following cycle of chemotherapy (<xref ref-type="fig" rid="fig2">Figure 2</xref>). At the end of the intervention, patients in the active arm continued their remaining chemotherapy cycles without any acupuncture treatment. Patients in the control arm were offered the active acupuncture protocol immediately after they completed the four weeks of blood sampling as a courtesy.</p><p>Based on previous trials [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>], blood samples were collected at baseline (preintervention) 7 days before chemotherapy and then every 7 days during four weeks. Blood samples of both groups, experimental and control, were taken under the same conditions.</p></sec><sec id="sec2.3"><title>2.3. Acupuncture Protocol</title><p>All acupuncture treatments were performed at S. Jo&#x000e3;o and Vila Nova de Gaia/Espinho Hospital Centres, Porto, Portugal. The acupuncture treatments were administered only by one acupuncturist (the main researcher; master degree on TCM by the University of Porto). A standardized acupuncture protocol was developed based on the Heidelberg model of Chinese medicine (CM), in which CM is explained as a comprehensive model of system biology based on a technical understanding of the regulatory core termini of CM, such as Yin, Yang, the phases, and the Shan Hang Lung theory [<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>].</p><p>The experimental group (AcuMoxa): acupuncture points and their anatomical locations were as follows: lower extremity (LV3, ST36, SP3, and GB39) and upper extremity (LI4, PC5, TB5, and LU7), and disposable acupuncture needles with a size of 36&#x02009;G, 0.20 &#x000d7; 25&#x02009;mm (Tewa). The depth of needling was at approximately 10&#x02009;mm. The<italic> de qi</italic> sensation was required [<xref rid="B18" ref-type="bibr">18</xref>]. Smokeless moxibustion treatment was used in the following points: SI6, TB5, ST32, and CV6; 2 minutes per point. Each session had a duration of 45 minutes.</p></sec><sec id="sec2.4"><title>2.4. Clinical and Laboratory Evaluation</title><p>Complete blood counts were collected at baseline and then once every 7 days at 3 time points during the study period (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The timing for collecting blood samples was based on previous trials [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>].</p><p>Lymphocyte populations T, B, and NK were analysed by flow cytometry (Coulter, EPICS XL-MCL flow cytometer) with a combination of monoclonal antibodies anti-CD3-FITC/(CD56 + CD16)-PE (Immunotech).</p><p>Anxiety and depression scores as well as patients quality of life were assessed through Hospital anxiety and depression scale (HADS) and EORTC-QoL CR-29 questionnaires, respectively, in the beginning and at the end of the study for both groups.</p></sec><sec id="sec2.5"><title>2.5. Statistical Analysis</title><p>This study was designed to provide preliminary data about its feasibility and analysis to support a subsequent large-scale, fully powered study to evaluate the effects of acupuncture on NK cells in patients with CRC.</p><p>Differences between groups were assessed through Mann-Whitney <italic>U</italic> test. Intragroup analyses were assessed by Friedman test. In order to explore variables correlations, the Pearson correlation analyses was performed. Missing data were handled based on available data approach. SPSS for Windows was used for statistical computation. Results yielding a <italic>P</italic> value &#x0003c; 0.05, with alpha = 0.05 and C.I. level = 95, were considered statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Baseline Sample Characterization</title><p>At baseline, patients in both groups shared similar demographic and clinical characteristics (<xref ref-type="table" rid="tab1">Table 1</xref>). The majority of patients (88.9%) have a colon cancer, with Stage II (16.7%) and Stage III (55.6%); 66.7% of the patients were submitted to the FOLFOX and 16.7% to XELOX chemotherapy regimens.</p><p>Comparison of blood analyses at baseline showed no statistical differences among groups (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>A total of&#x02009;&#x02009;&#x02009;18 (100%) patients completed the questionnaires of QOL-CR29 and HADS at the beginning and at the end of the study.</p><p>Comparison of QOL and anxiety and depression scores at baseline did not reveal any statistical differences among groups (<xref ref-type="table" rid="tab1">Table 1</xref>); however the experimental group revealed high scores of depression.</p></sec><sec id="sec3.2"><title>3.2. Effect of Acupuncture on WBC and ANC</title><p>The effects of acupuncture treatment on WBC counts and ANC in study patients are shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Comparison analyses between the two groups showed that AcuMoxa group had statistically significant higher values on WBC (<italic>P</italic> = 0.036) as well as on ANC (<italic>P</italic> = 0.046) at time point <italic>T</italic>
<sub>3</sub>.</p><p>Within group analyses showed that the changes in each group across time were significant: in the control group diminishing levels of WBC were seen (<italic>&#x003c7;</italic>
<sup>2</sup> = 7.8, <italic>P</italic> = 0.046, <italic>n</italic> = 8); on AcuMoxa group (<italic>n</italic> = 9), there was an increasing level of these parameters overtime (<italic>&#x003c7;</italic>
<sup>2</sup> = 11.011, <italic>P</italic> = 0.012; <italic>&#x003c7;</italic>
<sup>2</sup> = 11.966, <italic>P</italic> = 0.012, resp.) as well as the ANC (<italic>P</italic> = 0.007).</p></sec><sec id="sec3.3"><title>3.3. Effect of Acupuncture on Lymphocyte Populations</title><p>Although differences on total lymphocyte populations among control and experimental group were identified only after 6 sessions of AcuMoxa treatment (<italic>P</italic> = 0.021), higher values of B cells at time point <italic>T</italic>
<sub>1</sub> (<italic>P</italic> = 0.009) and <italic>T</italic>
<sub>3</sub> (<italic>P</italic> = 0.002) were seen in the AcuMoxa group. With respect to T cells, no statistical differences among groups were found (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>Total lymphocytes as well as B and T cells intragroup analyses did not reveal differences across time.</p></sec><sec id="sec3.4"><title>3.4. Effect of Acupuncture on NK Cells</title><p>Comparison between groups showed significant higher values of NK cells on the AcuMoxa group from time point <italic>T</italic>
<sub>1</sub> until time point <italic>T</italic>
<sub>3</sub> (<italic>P</italic> = 0.002, <italic>P</italic> = 0.003 and <italic>P</italic> = 0.000, resp.) (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>Within group analyses revealed significant increases on NK cells across time (<italic>&#x003c7;</italic>
<sup>2</sup> = 7.8, <italic>P</italic> = 0.046, <italic>n</italic> = 8), while the control group showed a significant decrease of NK cells (<italic>&#x003c7;</italic>
<sup>2</sup> = 7.65, <italic>P</italic> = 0.049, <italic>n</italic> = 8).</p></sec><sec id="sec3.5"><title>3.5. Effect of Acupuncture on Anxiety and Depression Levels</title><p>The comparison between the two groups did not reveal significant differences on anxiety (0.050) and depression levels (0.094) (<xref ref-type="fig" rid="fig6">Figure 6</xref>). However, when analyzing each group, it was shown that the experimental group had a significant decrease depression mean (<italic>P</italic> = 0.027), whereas in the control group the anxiety (<italic>P</italic> = 0.031) and depression (<italic>P</italic> = 0.027) levels increased significantly. In addition, exploratory analyses on a possible correlation between NK cells and depression and anxiety levels did not reveal any significant correlation, despite the observation of a decrease on anxiety and depression levels along with an increase of NK cells.</p></sec><sec id="sec3.6"><title>3.6. Effect of Acupuncture on Patients QOL</title><p>With respect to the analyses of the different items of QOL questionnaires, no significant differences were identified between the control and experimental groups (<xref ref-type="fig" rid="fig7">Figure 7</xref>). However, data collected from QOL questionnaires showed a tendency of reduction of several symptoms such as gastrointestinal symptoms, urological symptoms, stoma-related symptoms, male sexual dysfunction, and chemotherapy side effects (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>Intragroup variability analyses showed a significant decrease of chemotherapy side effects (<xref ref-type="fig" rid="fig8">Figure 8</xref>) on the experimental group (<italic>P</italic> = 0.034).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The host immune system functional state has a major prognostic and predictive impact on the outcome of cancer patients treated with conventional or targeted chemotherapies [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>Several authors revealed that acupuncture modulates NK cell number and function in diverse clinical situations such as in women with severe anxiety [<xref rid="B19" ref-type="bibr">19</xref>], in pain syndromes [<xref rid="B20" ref-type="bibr">20</xref>], and in healthy volunteers [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>Studies regarding the effect of acupuncture and moxibustion on CRC patients are scarce. In fact, only two eastern studies have addressed modulation of NK cells activity in CRC patients [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>].</p><p>To the best of our knowledge, this research protocol is the first study on acupuncture for cancer patients conducted in the Portuguese National Health System and is the first controlled clinical trial on the West that addressed acupuncture and moxibustion NK cells modulation, its implications on psychoemotional state, and on the QOL of CRC patients.</p><p>Although our data must be carefully interpreted due to methodological limitations, some conclusions may be pointed out.</p><p>Firstly, we observed (1) a reduction on anxiety and depression and (2) consistent positive trends on the levels of WBC, ANC, and B and NK cells in the AcuMoxa group versus the control group. The increase on WBC and ANC resulted in approximately a 1.5x reduction in leukopenia and neutropenia rates. The acupuncture group showed a twofold increase in NK cells rate compared to the control group. These preliminary results indicate an immunomodulatory effect of acupuncture in CRC patients undergoing chemotherapy. Acupuncture stimulation may yield a myeloprotective effect as suggested by Lu et al. on a study on electroacupuncture plus TDP infrared lamp effect in gynaecologic malignancies. Despite the differences in the selection of acupoints and type of acupuncture, WBC and ANC levels were similar to those obtained by Lu et al.</p><p>Secondly, our preliminary results show that acupuncture benefits the emotional status by decreasing anxiety and depression levels. This effect may contribute to improvement on NK cells activity. As reported recently on a study on women with breast cancer [<xref rid="B26" ref-type="bibr">24</xref>], the emotional state influences NK cells numbers and activity.</p><p>Thirdly, with respect to quality of life, our study did not reveal significant differences between the two groups. However, we observed a tendency for decreasing certain symptoms on the AcuMoxa group, such as gastrointestinal and urological symptoms and chemotherapy side effects as well as the improvement of sexual function in men. This is probably due to the short period of treatment. In addition, intragroup analyses reveal a significant decrease of chemotherapy side effects on the AcuMoxa group indicating an overtime protective role of acupuncture for CRC patients during chemotherapy.</p><p>Fourthly, no acupuncture and moxibustion-related adverse events were observed. Globally, these preliminary results indicate that our AcuMoxa protocol is feasible and safe for CRC patients undergoing chemotherapy.</p><p>What may be the physiological explanation for the observed results of AcuMoxa stimulation?</p><p>It is generally accepted that acupuncture induces an increase on the release of <italic>&#x003b2;</italic>-endorphin [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B23" ref-type="bibr">23</xref>] via the stimulation of the HPA axis. <italic>&#x003b2;</italic>-Endorphins consequently influence immune cells by binding to opioid receptors on the surface of the cells, namely, on NK cells [<xref rid="B27" ref-type="bibr">25</xref>] promoting the expression of cytotoxic molecules and the production of IFN<italic>&#x003b3;</italic>. In turn, IFN<italic>&#x003b3;</italic> would further increase the expression of NK cells receptors and cytokine secretion by other immune cells, thereby amplifying anticancer immune functions.</p><p>The HPA axis and SNS are generally activated in cancer, resulting in high levels of catecholamine and glucocorticoids, which augments the sympathetic outflow and decreases NK activity in the periphery [<xref rid="B27" ref-type="bibr">25</xref>].</p><p>Therefore, we may hypothesize that acupuncture, by acting on the SNS and the HPA axis, may reduce the levels of catecholamines and consequently attenuate their suppressive effects on NK cells.</p><p>There are limitations in our preliminary study to be considered.<list list-type="order"><list-item><p>Although the patients were randomly allocated in each group, there is the possibility that results may have occurred by chance due to the small sample size. A larger study based on this protocol is required to precisely evaluate the effects of acupuncture on CRC patients during chemotherapy and to explore the relation of the cancer severity and different types of chemotherapy on the possible acupuncture immunomodulatory effect. Nevertheless, the small sample of patients allowed assessing the trial feasibility and preliminary data on efficacy.</p></list-item><list-item><p>Another limitation of our study was the heterogeneity on chemotherapy protocols which may have influenced the hypothesized AcuMoxa effects and results.</p></list-item><list-item><p>Finally, the short duration of the study did not allow obtaining more precise data regarding the impact of acupuncture on patients QOL and prognosis.</p></list-item></list>
</p></sec><sec id="sec5"><title>5. Conclusions</title><p>Our pilot study suggests that acupuncture and moxibustion may (1) stimulate anticancer immunity, (2) promote a myeloprotective effect, (3) improve the psychoemotional status and quality of life, and (4) minimize chemotherapy side effects.</p><p>This study protocol proved to be feasible and safe for CRC patients.</p><p>A larger and long-term acupuncture trial is needed to clarify acupuncture's immunomodulatory effects in CRC. If this effect is ultimately established, then this treatment may serve as a possible complementary therapy for CRC treatment and possibly contribute to improving patients' prognosis and quality of life.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to all the nurse staff from the Departaments of Oncology of V.N.Gaia/Espinho and S. Jo&#x000e3;o Hospital Centers, Oporto, Portugal, for their contribution on collecting blood samples as well as to the administrative personnel involved in this project.</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Immune parameters affecting the efficacy of chemotherapeutic regimens</article-title><source><italic>Nature Reviews Clinical Oncology</italic></source><year>2011</year><volume>8</volume><issue>3</issue><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="other">2-s2.0-79952390627</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>The immunobiology of cancer immunosurveillance and immunoediting</article-title><source><italic>Immunity and Immunoediting</italic></source><year>2004</year><volume>21</volume><issue>2</issue><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="other">2-s2.0-4143141823</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mordoh</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>EM</given-names></name><name><surname>Roberti</surname><given-names>MP</given-names></name></person-group><article-title>Natural killer cells in human cancer: from biological functions to clinical applications</article-title><source><italic>Journal of Biomedicine and Biotechnology</italic></source><year>2011</year><volume>2011</volume><fpage>11 pages</fpage><pub-id pub-id-type="publisher-id">676198</pub-id><pub-id pub-id-type="other">2-s2.0-79959350453</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000fc;ssler</surname><given-names>NC</given-names></name><name><surname>Strange</surname><given-names>BJ</given-names></name><name><surname>Petzold</surname><given-names>M</given-names></name><name><surname>Nussler</surname><given-names>AK</given-names></name><name><surname>Glanemann</surname><given-names>OGM</given-names></name></person-group><article-title>Reduced NK-cell activity in patients with metastatic colon cancer</article-title><source><italic>Experimental and Clinical Sciences</italic></source><year>2007</year><volume>6</volume><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D-H</given-names></name><name><surname>Park</surname><given-names>N-J</given-names></name><name><surname>McArdle</surname><given-names>T</given-names></name></person-group><article-title>Cancer-specific stress and mood disturbance: implications for symptom perception, quality of life, and immune response in women shortly after diagnosis of breast cancer</article-title><source><italic>ISRN Nursing</italic></source><year>2012</year><volume>2012</volume><fpage>7 pages</fpage><pub-id pub-id-type="publisher-id">608039</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joos</surname><given-names>S</given-names></name><name><surname>Brinkhaus</surname><given-names>B</given-names></name><name><surname>Maluche</surname><given-names>C</given-names></name><etal/></person-group><article-title>Acupuncture and moxibustion in the treatment of active Crohn&#x02019;s disease: a randomized controlled study</article-title><source><italic>Digestion</italic></source><year>2004</year><volume>69</volume><issue>3</issue><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="other">2-s2.0-3042535796</pub-id><pub-id pub-id-type="pmid">15114043</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavoussi</surname><given-names>B</given-names></name><name><surname>Ross</surname><given-names>BE</given-names></name></person-group><article-title>The neuroimmune basis of anti-inflammatory acupuncture</article-title><source><italic>Integrative Cancer Therapies</italic></source><year>2007</year><volume>6</volume><issue>3</issue><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="other">2-s2.0-34548139770</pub-id><pub-id pub-id-type="pmid">17761638</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Sumino</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name></person-group><article-title>Acupuncture modifies immune cells</article-title><source><italic>Journal of Experimental and Clinical Medicine</italic></source><year>2009</year><volume>1</volume><issue>1</issue><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="other">2-s2.0-77949304116</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keun Kim</surname><given-names>C</given-names></name><name><surname>Gi</surname><given-names>SC</given-names></name><name><surname>Sang</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Electroacupuncture up-regulates natural killer cell activity: identification of genes altering their expressions in electroacupuncture induced up-regulation of natural killer cell activity</article-title><source><italic>Journal of Neuroimmunology</italic></source><year>2005</year><volume>168</volume><issue>1-2</issue><fpage>144</fpage><lpage>153</lpage><pub-id pub-id-type="other">2-s2.0-25844495868</pub-id><pub-id pub-id-type="pmid">16154208</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>GS</given-names></name><name><surname>Han</surname><given-names>JB</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Effects of moxibustion to zusanli (ST36) on alteration of natural killer cell activity in rats</article-title><source><italic>The American Journal of Chinese Medicine</italic></source><year>2004</year><volume>32</volume><issue>2</issue><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="other">2-s2.0-3542998762</pub-id><pub-id pub-id-type="pmid">15315267</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Bae</surname><given-names>H</given-names></name></person-group><article-title>Acupuncture and immune modulation</article-title><source><italic>Autonomic Neuroscience: Basic and Clinical</italic></source><year>2010</year><volume>157</volume><issue>1-2</issue><fpage>38</fpage><lpage>41</lpage><pub-id pub-id-type="other">2-s2.0-77957883397</pub-id><pub-id pub-id-type="pmid">20399151</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Kaneuchi</surname><given-names>M</given-names></name><name><surname>Nishiya</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer</article-title><source><italic>Cancer Chemotherapy and Pharmacology</italic></source><year>2002</year><volume>50</volume><issue>2</issue><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="other">2-s2.0-0036351313</pub-id><pub-id pub-id-type="pmid">12172979</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Matulonis</surname><given-names>UA</given-names></name><name><surname>Doherty-Gilman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial</article-title><source><italic>Journal of Alternative and Complementary Medicine</italic></source><year>2009</year><volume>15</volume><issue>7</issue><fpage>745</fpage><lpage>753</lpage><pub-id pub-id-type="other">2-s2.0-67749088590</pub-id><pub-id pub-id-type="pmid">19552597</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>HJ</given-names></name></person-group><source><italic>Kursbuch Traditionelle Chinesische Medizin</italic></source><year>2007</year><edition>2nd edition</edition><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Thieme</publisher-name><series>Textbook of TCM</series></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>HJ</given-names></name></person-group><article-title>Chinesische medizin als vegetative systembiologie</article-title><source><italic>HNO</italic></source><year>2011</year><volume>59</volume><issue>12</issue><fpage>1160</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">22159335</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>HJ</given-names></name></person-group><article-title>[Chinese medicine as vegetative systems biology: part II: the structure of TCM diagnosis]</article-title><source><italic>HNO</italic></source><year>2011</year><volume>59</volume><fpage>1165</fpage><lpage>1175</lpage><comment>(IF 2011: 0,400)</comment><pub-id pub-id-type="pmid">22159336</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>HJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>GH</given-names></name><name><surname>Wu</surname><given-names>GC</given-names></name></person-group><article-title>Chinese medicine as a model of system biology&#x02014;diagnosis as the foundation of acupoint selection</article-title><source><italic>Current Research in Acupuncture (Research Monograph)</italic></source><year>2012</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langevin</surname><given-names>HM</given-names></name><name><surname>Churchill</surname><given-names>DL</given-names></name><name><surname>Fox</surname><given-names>JR</given-names></name><name><surname>Badger</surname><given-names>GJ</given-names></name><name><surname>Garra</surname><given-names>BS</given-names></name><name><surname>Krag</surname><given-names>MH</given-names></name></person-group><article-title>Biomechanical response to acupuncture needling in humans</article-title><source><italic>Journal of Applied Physiology</italic></source><year>2001</year><volume>91</volume><issue>6</issue><fpage>2471</fpage><lpage>2478</lpage><pub-id pub-id-type="other">2-s2.0-0035190306</pub-id><pub-id pub-id-type="pmid">11717207</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arranz</surname><given-names>L</given-names></name><name><surname>Guayerbas</surname><given-names>N</given-names></name><name><surname>Siboni</surname><given-names>L</given-names></name><name><surname>De la Fuente</surname><given-names>M</given-names></name></person-group><article-title>Effect of acupuncture treatment on the immune function impairment found in anxious women</article-title><source><italic>The American Journal of Chinese Medicine</italic></source><year>2007</year><volume>35</volume><issue>1</issue><fpage>35</fpage><lpage>51</lpage><pub-id pub-id-type="other">2-s2.0-33846781525</pub-id><pub-id pub-id-type="pmid">17265549</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petti</surname><given-names>F</given-names></name><name><surname>Bangrazi</surname><given-names>A</given-names></name><name><surname>Liguori</surname><given-names>A</given-names></name><name><surname>Reale</surname><given-names>G</given-names></name><name><surname>Ippoliti</surname><given-names>F</given-names></name></person-group><article-title>Effects of acupuncture on immune response related to opioid-like peptides</article-title><source><italic>Journal of Traditional Chinese Medicine</italic></source><year>1998</year><volume>18</volume><issue>1</issue><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="other">2-s2.0-0032009265</pub-id><pub-id pub-id-type="pmid">10437265</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Sakuma</surname><given-names>M</given-names></name><etal/></person-group><article-title>Acupuncture regulates leukocyte subpopulations in human peripheral blood</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2007</year><volume>4</volume><issue>4</issue><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="other">2-s2.0-38149010514</pub-id><pub-id pub-id-type="pmid">18227912</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Effect of acupuncture on the activity of the peripheral blood T lymphocyte subsets and NK cells in patients with colorectal cancer liver metastasis</article-title><source><italic>Chinese acupuncture &#x00026; moxibustion</italic></source><year>2010</year><volume>30</volume><issue>1</issue><fpage>10</fpage><lpage>12</lpage><pub-id pub-id-type="other">2-s2.0-77951641592</pub-id><pub-id pub-id-type="pmid">20353106</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name></person-group><article-title>[Effects of warming needle moxibustion on improvement of gastrointestinal and immune function in patients with postoperation of colorectal cancer</article-title><source><italic>Zhongguo Zhen Jiu</italic></source><year>2011</year><volume>31</volume><issue>6</issue><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="other">2-s2.0-79961114862</pub-id><pub-id pub-id-type="pmid">21739693</pub-id></element-citation></ref><ref id="B26"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>MF</given-names></name><name><surname>Ortiz S&#x000c3;nchez</surname><given-names>E</given-names></name><name><surname>Vujanovic</surname><given-names>NL</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Acupuncture may stimulate anticancer immunity via activation of natural killer cells</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2011</year><volume>2011</volume><fpage>14 pages</fpage><pub-id pub-id-type="publisher-id">481625</pub-id><pub-id pub-id-type="other">2-s2.0-79955097313</pub-id></element-citation></ref><ref id="B27"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>B</given-names></name></person-group><article-title>The acupuncture approach to the hypothalamus-pituitary-adrenal axis and its interaction with the sympathetic and parasympathetic systems</article-title><source><italic>Journal of Biomedical Therapy</italic></source><year>2009</year><volume>3</volume><issue>1</issue><fpage>22</fpage><lpage>25</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>CONSORT flow of participants through the study.</p></caption><graphic xlink:href="ECAM2014-217397.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Study flow chart. Black solid dots: time points of outcome measurements. Open circle: first chemotherapy day. Black diamonds: the primary endpoints of the study. Dashed lines: the expected changes, during chemotherapy, of white blood cells (WBC) and absolute neutrophil counts (ANC). Short, blue down arrows: acupuncture treatments. CBC, complete blood counts; NK, NK cells and subsets.</p></caption><graphic xlink:href="ECAM2014-217397.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>WBC and ANC. Comparison between groups.</p></caption><graphic xlink:href="ECAM2014-217397.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Total lymphocytes and T and B cells. Comparison between groups.</p></caption><graphic xlink:href="ECAM2014-217397.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Total NK cells counts. Comparison between groups.</p></caption><graphic xlink:href="ECAM2014-217397.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>HADS scores. Differences among groups, at beginning (<italic>T</italic>
<sub>0</sub>) and at the end (<italic>T</italic>
<sub>3</sub>) of the study.</p></caption><graphic xlink:href="ECAM2014-217397.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Symptoms related to QOL questionnaires. Differences among groups at the beginning (<italic>T</italic>
<sub>0</sub>) and at the end (<italic>T</italic>
<sub>3</sub>) of the study. CT, control group; AcuMoxa, experimental group.</p></caption><graphic xlink:href="ECAM2014-217397.007"/></fig><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Chemotherapy side effects. Intragroup analyses show significant decrease of chemotherapy side effects among AcuMoxa group.</p></caption><graphic xlink:href="ECAM2014-217397.008"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline comparison between groups: sociodemographic and clinical characteristics; blood analyses and QOL-CR 29 and HADS scores.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">Experimental group (<italic>n</italic> = 9)</th><th align="center" rowspan="1" colspan="1">Control group (<italic>n</italic> = 9)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mean; range</td><td align="center" rowspan="1" colspan="1">62.2; 38&#x02013;74</td><td align="center" rowspan="1" colspan="1">56.6; 43&#x02013;74</td></tr><tr><td align="left" rowspan="1" colspan="1">Cancer type</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Colon</td><td align="center" rowspan="1" colspan="1">8 (88.9%)</td><td align="center" rowspan="1" colspan="1">9 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rectum</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor staging</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;II</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">2 (22.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;III</td><td align="center" rowspan="1" colspan="1">7 (77.8)</td><td align="center" rowspan="1" colspan="1">3 (33.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IV</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">4 (44.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of chemotherapy</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FOLFOX</td><td align="center" rowspan="1" colspan="1">6 (66.7%)</td><td align="center" rowspan="1" colspan="1">6 (66.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;XELOX</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">2 (22.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FOLFIRI</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Capecitabine</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood analyses (<italic>P</italic> value)</td><td align="center" rowspan="1" colspan="1">
<bold>(mean cells/</bold>
<bold><italic>&#x003bc;</italic></bold>
<bold>L; s.d.)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>(mean cells/</bold>
<bold><italic>&#x003bc;</italic></bold>
<bold>L; s.d.)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;WBC (<italic>P</italic> = 0.400)</td><td align="center" rowspan="1" colspan="1">6367.78; 897.55 </td><td align="center" rowspan="1" colspan="1">5915.56; 1288.59</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ANC (<italic>P</italic> = 0.864)</td><td align="center" rowspan="1" colspan="1">3128.78; 996.25</td><td align="center" rowspan="1" colspan="1">3219; 1199.07</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total lymphocyte (<italic>P</italic> = 0.736)</td><td align="center" rowspan="1" colspan="1">1734.59; 586.98</td><td align="center" rowspan="1" colspan="1">1842.28; 735.77</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;B cells (<italic>P</italic> = 0.978)</td><td align="center" rowspan="1" colspan="1">170.88; 51.59</td><td align="center" rowspan="1" colspan="1">169.25; 168.91</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;T cells (<italic>P</italic> = 0.542)</td><td align="center" rowspan="1" colspan="1">1378.95; 540.62</td><td align="center" rowspan="1" colspan="1">1548.76; 613.11</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NK cells (<italic>P</italic> = 0.146)</td><td align="center" rowspan="1" colspan="1">184.52; 81.07</td><td align="center" rowspan="1" colspan="1">123.44; 88.46</td></tr><tr><td align="left" rowspan="1" colspan="1">QOL-Cr 29 and HADS scores (<italic>P</italic> value)</td><td align="center" rowspan="1" colspan="1">
<bold>(mean; s.d.)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>(mean; s.d.)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Anxiety (<italic>P</italic> = 0.722)</td><td align="center" rowspan="1" colspan="1">14.78; 6.45</td><td align="center" rowspan="1" colspan="1">15.67; 3.53</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Depression (<italic>P</italic> = 0.432)</td><td align="center" rowspan="1" colspan="1">16.11; 5.84</td><td align="center" rowspan="1" colspan="1">14.33; 3.12</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Urological symptoms (<italic>P</italic> = 0.632)</td><td align="center" rowspan="1" colspan="1">7.67; 1.00</td><td align="center" rowspan="1" colspan="1">7.89; 0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastrointestinal symptom (<italic>P</italic> = 0.609)</td><td align="center" rowspan="1" colspan="1">7.67; 2.74</td><td align="center" rowspan="1" colspan="1">8.44; 3.54</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Defecation symptoms (<italic>P</italic> = 0.78)</td><td align="center" rowspan="1" colspan="1">6.22; 6.05</td><td align="center" rowspan="1" colspan="1">10.67; 3.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Stoma-related symptoms (<italic>P</italic> = 0.66)</td><td align="center" rowspan="1" colspan="1">2.89; 4.40</td><td align="center" rowspan="1" colspan="1">&#x02014;<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chemo side effects (<italic>P</italic> = 0.96)</td><td align="center" rowspan="1" colspan="1">8.33; 1.93</td><td align="center" rowspan="1" colspan="1">6.67; 2.06</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male sexual function (<italic>P</italic> = 0.239)</td><td align="center" rowspan="1" colspan="1">3.00; 2.59</td><td align="center" rowspan="1" colspan="1">1.56; 2.40</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female sexual function (<italic>P</italic> = 0.148)</td><td align="center" rowspan="1" colspan="1">0.78; 1.20</td><td align="center" rowspan="1" colspan="1">1.78; 1.56</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Weight concerns (<italic>P</italic> = 0.857)</td><td align="center" rowspan="1" colspan="1">2.44; 1.24</td><td align="center" rowspan="1" colspan="1">2.56; 1.33</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Body image (<italic>P</italic> = 0.819)</td><td align="center" rowspan="1" colspan="1">4.56; 1.42</td><td align="center" rowspan="1" colspan="1">4.78; 2.49</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Future concerns (<italic>P</italic> = 0.398)</td><td align="center" rowspan="1" colspan="1">2.89; 1.36</td><td align="center" rowspan="1" colspan="1">3.33; 0.71</td></tr></tbody></table><table-wrap-foot><fn><p>
(S.d., standard deviation; <italic>P</italic> &#x0003c; 0.05 considered statistically significant; &#x02014;<sup>a</sup>, no patients with stoma bag on the control group.)</p></fn></table-wrap-foot></table-wrap></floats-group></article>